RBC Capital Remains a Buy on Legend Biotech (LEGN)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech yesterday and set a price target of $74.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Timashev is a 5-star analyst with an average return of 31.7% and a 58.00% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Exelixis, and Jazz Pharmaceuticals.
In addition to RBC Capital, Legend Biotech also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued on November 26. However, on November 21, TR | OpenAI – 4o reiterated a Hold rating on Legend Biotech (NASDAQ: LEGN).
Based on Legend Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $272.33 million and a GAAP net loss of $39.69 million. In comparison, last year the company earned a revenue of $160.21 million and had a GAAP net loss of $125.32 million
Read More on LEGN:
Disclaimer & DisclosureReport an Issue
- Legend Biotech highlights new CARVYKTI data in RRMM
- H.C. Wainwright says Legend Biotech competition concerns overdone
- Buy Rating for Legend Biotech Reaffirmed Due to CARVYKTI’s Strong Market Position and Proven Efficacy
- Legend Biotech price target raised to $75 from $66 at Cantor Fitzgerald
- Legend Biotech price target lowered to $90 from $94 at Barclays
